Search results
Beta-2-glycoprotein I (B2GPI) binds anionic phospholipids and is considered to be the predominant antigen in APS and antibodies against B2GPI (anti-B2GPI) are recognised in the laboratory criteria for APS diagnosis.
14 paź 2021 · Anti-β-2 glycoprotein I antibodies (anti-B2GPI) are often cited as the major pathogenically relevant antibody in antiphospholipid syndrome (APS), but it is unclear if there is clinical evidence to support this theory.
Beta-2-Glycoprotein I (β2GPI) plays a number of essential roles throughout the body. β2GPI, C-reactive protein and thrombomodulin are the only three proteins that possess the dual capability to up and down regulate the complement and coagulation systems depending upon external stimulus.
In this review we discuss the characteristics of β(2)GPI; the generation, pathogenic effects, and standardized testing of anti-β(2)GPI antibodies; and the potential use of therapies that target the β(2)GPI/anti-β(2)GPI interaction in the treatment of APS.
1 sie 2019 · Recent advances allow us to propose antibodies targeting beta-2-glycoprotein I (β 2 -GPI) as the most specific antibodies associated with anti-phospholipid syndrome (APS). Therefore, there is now a crucial need for powerful biological assays to adequately monitor them.
12 lip 2012 · In this overview, we will summarize our knowledge on the etiology of the autoantibodies, and we will discuss the evidence that identify autoantibodies against β 2 -glycoprotein I as the culprit of APS. Topics: autoantibodies, glycoprotein, antiphospholipid antibodies, antibodies, thrombosis, thrombus, phospholipids.
4 lis 2021 · Beta 2-glycoprotein 1 (ß2GP1) is the main antigen recognized by aPL and plays an essential role in the pathogenesis of APS.
